# Pacira BioSciences, Inc.

> Pacira BioSciences (Nasdaq: PCRX) is a U.S. biopharmaceutical company built around a single, stubborn idea: surgery and chronic pain should not require a bottle of opioids. Its flagship product, EXPAREL, a long-acting local anesthetic built on the proprietary DepoFoam multivesicular-liposome delivery platform, anchors a portfolio that also includes the ZILRETTA knee-osteoarthritis injection and the iovera handheld cryoanalgesia device. With roughly 790 employees and about $726 million in 2025 revenue, Pacira is pushing beyond established analgesics into gene therapy (PCRX-201) under a '5x30' growth strategy aimed at reinventing how the world treats pain.

- **Founded:** 2006
- **Headquarters:** Tampa, Florida, United States
- **Founders:** Pacira (originally founded as 21st Century BioPharmaceuticals) (Founded 2006 in Summit, New Jersey; spun out from SkyePharma's San Diego operations)
- **Team size:** ~790 employees
- **Products:** EXPAREL (bupivacaine liposome injectable suspension), ZILRETTA (triamcinolone acetonide extended-release injectable suspension), iovera system, PCRX-201 (enekinragene inzadenovec)
- **Notable:** Launched EXPAREL in 2012, establishing the modern non-opioid postsurgical analgesia category, Reached more than 2.5 million patients in 2025 and achieved the highest gross margins in company history, Acquired Flexion Therapeutics for ~$630M in 2021, adding the ZILRETTA franchise

## Products & services

- **EXPAREL (bupivacaine liposome injectable suspension)** — Long-acting local analgesic built on the proprietary DepoFoam multivesicular-liposome platform, delivering postsurgical pain control for days from a single dose. Pacira's flagship product, launched in the U.S. in 2012.
- **ZILRETTA (triamcinolone acetonide extended-release injectable suspension)** — The first and only FDA-approved extended-release intra-articular injection for osteoarthritis-related knee pain, gained through the 2021 Flexion Therapeutics acquisition.
- **iovera system** — A handheld, drug-free cryoanalgesia device that applies precise, controlled doses of cold to targeted nerves for immediate, long-lasting pain relief; FDA 510(k)-cleared SmartTip for chronic low back pain via medial branch nerve block.
- **PCRX-201 (enekinragene inzadenovec)** — Investigational, locally administered gene therapy in Phase 2 (ASCEND study) for moderate-to-severe knee osteoarthritis, built on a high-capacity adenovirus (HCAd) vector platform.

## Achievements

- Launched EXPAREL in 2012, establishing the modern non-opioid postsurgical analgesia category
- Reached more than 2.5 million patients in 2025 and achieved the highest gross margins in company history
- Acquired Flexion Therapeutics for ~$630M in 2021, adding the ZILRETTA franchise
- Advanced PCRX-201, reported as the first gene therapy to reach these clinical milestones in knee osteoarthritis
- Received FDA 510(k) clearance for a new iovera SmartTip for chronic low back pain (2025)
- Secured EMA validation of EXPAREL's Marketing Authorization Application for the EU

## Latest updates

- **2026-02** — Reported full-year 2025 revenue of $726.4M (up 4%), with EXPAREL at $575.1M, ZILRETTA at $116.6M and iovera at $24.2M.
- **2025-06** — Unveiled three-year clinical data showing sustained efficacy and safety of investigational gene therapy PCRX-201 in moderate-to-severe knee osteoarthritis.
- **2025-02** — Acquired GQ Bio Therapeutics and its high-capacity adenovirus gene-therapy vector platform in support of the 5x30 strategy.
- **2025-01** — Announced new five-year (5x30) objectives and received FDA 510(k) clearance for a new iovera SmartTip for chronic low back pain.

## Links

- Website: https://www.pacira.com
- LinkedIn: https://www.linkedin.com/company/pacira-biosciences-inc-
- Twitter/X: https://twitter.com/PaciraBio
- YouTube: https://www.youtube.com/@PaciraBio
- Facebook: https://www.facebook.com/pages/Flexion-Therapeutics/302064119892248

---

Profile page: https://yespress.io/pacira-biosciences-inc
Published by YesPress — https://yespress.io
Last updated: 2026-06-20